Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View
Indication:
Epithelial Carcinomas
Location:
Texas Oncology-Canton
Phase: Ia/IIa
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PI/II Cholangiocarcinoma CX-4945 w Gem View
Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View
Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 3 Sit+Nivo vs. Docetaxel NSCLC View
Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Brain Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph 2 rib + non-ster AIs HR+ HER2- aBC View
Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3 Rituximab +/- Ibrutinib tx-naive FL View
Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Cervical Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1b/2 R/R FL, R/R DLBCL View
Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 BGB-3111 R/R MZL View
Description: A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma (BGB-3111-214)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Esophageal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3b 1L CLL debulk combo View
Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Liver Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1/2 AGEN1884 Adv Refractory cancer View
Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)
Indication:
Liver Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph4 Ixazomib+Lena & Dex MM (MM-6) View
Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View
Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III/IV
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Atezo Rollover for GNE & Roche View
Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II/III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 Adj canakinumab NSCLC View
Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View
Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 3 Sit+Nivo vs. Docetaxel NSCLC View
Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Skin Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 Rituximab +/- Ibrutinib tx-naive FL View
Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 FIH TP-1287 Solid tumor View
Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b/2 R/R FL, R/R DLBCL View
Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 BGB-3111 R/R MZL View
Description: A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma (BGB-3111-214)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph4 Ixazomib+Lena & Dex MM (MM-6) View
Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Skin Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 FIH TP-1287 Solid tumor View
Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II